They’ve been rewarded enough (~$14.65B USD net profit 2024), and are lucky they’re allowed to capture any further economic benefit from the sale of a simple compound (imho).
... a simple compound that was already developed and in-use, so the current patent (the one that's made it a big, ongoing news story and a kind of social phenomenon) is rewarding only going through the approval process for using it for weight loss, specifically, not development of a new drug.
> In the 1970s, Jens Juul Holst and Joel Habener began research on the GLP-1 hormone [...] Research continued, and in 1993, Michael Nauck managed to infuse GLP-1 into people with type 2 diabetes, stimulating insulin while inhibiting glucagon and bringing blood glucose to normal levels. However, treating diabetes patients with GLP-1 hormones resulted in significant side effects, leading researchers financed by Novo Nordisk to start looking to develop a suitable compound for therapeutic use. In 1998, a team of researchers at Novo Nordisk led by the scientist Lotte Bjerre Knudsen developed liraglutide, a glucagon-like peptide-1 receptor agonist that could be used to treat diabetes.
GLP-1 is a hormone that naturally occurs in the human body. Novo Nordisk was responsible for turning it into a diabetes medication. They were responsible for turning it into a weight loss medication.